Paul Meeks of Freedom Capital Markets says he is "a little bit worried" about Cerebras (CBRS) after the move the stock has made today ahead of its earnings report. "I definitely would not buy this ahead of earnings," he tells @NPetallides, adding that it's "risky and overvalued." He has the lowest price target on the Street for $CBRS at $209. For more market news, tune in at:

🌙 What a room at Build N Build Night! On the sidelines of SBC, YZi Labs & @BNBChain brought researchers, founders, and investors under one roof to explore how technical breakthroughs become products, companies, and new markets. Thank you to everyone who joined us in Palo Alto. We can’t wait to do it again! 🤝 @BNBChain @CBRStanford @initc3org @theBBFund @StanfordSBA

If UBS is correct here, $CBRS is going to be a nice performer.. "Our conversations with experts and takeaways from recent industry events suggest compute is likely to continue moving along disaggregation route which offers significant performance improvement on the system level. Although AWS has not yet been fully formalized, we think the upside scenario would imply some deployment ratio of CBRS WSE CS- 3/4 per Trainium 3 rack (we estimate at 20K in C2026), but also potentially deployed alongside older racks too. We estimate AWS shipments potentially reaching $4-10B/yr before the end of the decade and think the opportunity may be measured in $10Bs in annual hardware shipments over the longer term. Beyond AWS, we see MSFT potentially interested in disaggregated solution over time, once MAIA 300/400 are ramped and widely deployed."